{
    "code": "60001050",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60001050",
    "time": "2019-09-13 03:04:48",
    "許可證字號": "衛部菌疫輸字第001050號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "111\/07\/17",
    "發證日期": "106\/07\/17",
    "許可證種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA06000105002",
    "中文品名": "癌自禦 注射劑",
    "英文品名": "Tecentriq",
    "適應症": "(1)適用於治療接受含鉑化學治療後疾病惡化或不適合含cisplatin療法之局部晚期或轉移性泌尿道上皮癌患者。 \r\n(2)單獨使用，適用於治療接受含鉑化學治療後，疾病惡化之局部晚期或轉移性非小細胞肺癌患者。患者若具有EGFR或ALK腫瘤基因異常，則須先經EGFR或ALK抑制劑治療，若治療後疾病惡化方可使用Tecentriq。\r\n(3)與Avastin(bevacizumab)、paclitaxel和carboplatin併用，做為轉移性， 不具有EGFR或ALK腫瘤基因異常之非鱗狀非小細胞肺癌的第一線治療藥物。\r\n(4)Tecentriq與nab-paclitaxel併用，適用於治療無法切除之局部晚期或轉移性三陰性乳癌，且腫瘤具PD-L1表現(tumor-infiltrating immune cells (IC) ≥ 1%)且未曾接受化療用於轉移性乳癌之病患。",
    "劑型": "27D注射液劑",
    "包裝": "玻璃小瓶裝 100支以下盒裝",
    "": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "-->\r\n                    \r\n                        \r\n                            標籤、仿單及包裝加註": [
        ""
    ],
    "藥品類別": "05限由醫師使用",
    "主成分略述": "Atezolizumab",
    "主製造廠": {
        "申請商名稱": "1901701100  羅氏大藥廠股份有限公司",
        "申請商地址": "台北市信義區松仁路100號40樓、40樓之1、41樓之1",
        "主製造廠": "",
        "製造廠名稱": "FCH0257000  F. HOFFMANN-LA ROCHE LTD."
    },
    "CCC號列": "",
    "藥理治療分類": "",
    "次製造廠": [
        {
            "製造廠名稱": "1225204000  裕利股份有限公司",
            "製造廠廠址": "桃園市大園區和平里1鄰開和路91號",
            "製造廠公司地址": "",
            "製造廠國別": "TAIWAN",
            "製程": "貼標廠"
        },
        {
            "製造廠名稱": "FCH0093000  F.HOFFMANN-LA ROCHE LTD.",
            "製造廠廠址": "GRENZACHERSTRASSE 124, CH-4070 BASEL,SWITZERLAND",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": "主成分(drug substance)製造廠"
        },
        {
            "製造廠名稱": "FCH0208000  F.HOFFMANN-LA ROCHE LTD.",
            "製造廠廠址": "WURMISWEG, CH-4303 KAISERAUGST, SWITZERLAND",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": "包裝"
        }
    ],
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013001500",
            "成分名稱": "Atezolizumab",
            "含量描述": "",
            "含量": "60.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "Tecentriq PI_190902-108-09-05.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001050&Seq=005&Type=9"
        },
        {
            "title": "20190626_Carton-108-07-09.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001050&Seq=008&Type=8"
        },
        {
            "title": "20190626_Vial Label-108-07-09.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001050&Seq=007&Type=8"
        },
        {
            "title": "瓶身標籤_Kaiseraugst site-108-06-19.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001050&Seq=006&Type=8"
        },
        {
            "title": "外盒_Kaiseraugst site-108-06-19.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001050&Seq=005&Type=8"
        },
        {
            "title": "100010500004-108-01-30-108-02-18(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001050&Seq=004&Type=8"
        },
        {
            "title": "100010500004-106-09-18.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001050&Seq=003&Type=8"
        },
        {
            "title": "100010500003-106-09-18.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001050&Seq=002&Type=8"
        },
        {
            "title": "100010500002-106-09-18.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001050&Seq=001&Type=8"
        }
    ]
}